Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
12
02
2021
accepted:
23
02
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) can result in a large variety of chronic health issues such as impaired lung function, reduced exercise performance and diminished quality of life. Our study aimed to investigate the efficacy, feasibility and safety of pulmonary rehabilitation in COVID-19 patients and to compare outcomes between patients with a mild/moderate and a severe/critical course of the disease. Patients in the post-acute phase of a mild to critical course of COVID-19 admitted to a comprehensive 3-week inpatient pulmonary rehabilitation programme were included in this prospective, observational cohort study. Several measures of exercise performance (6-min walk distance (6MWD)), lung function (forced vital capacity (FVC)) and quality of life (36-question short-form health survey (SF-36)) were assessed before and after pulmonary rehabilitation. 50 patients were included in the study (24 with mild/moderate and 26 with severe/critical COVID-19). On admission, patients had a reduced 6MWD (mild: median 509 m, interquartile range (IQR) 426-539 m; severe: 344 m, 244-392 m), an impaired FVC (mild: 80%, 59-91%; severe: 75%, 60-91%) and a low SF-36 mental health score (mild: 49 points, 37-54 points; severe: 39 points, 30-53 points). Patients attended a median (IQR) 100% (94-100%) of all provided pulmonary rehabilitation sessions. At discharge, patients in both subgroups improved in 6MWD (mild/moderate: +48 m, 35-113 m; severe/critical: +124 m, 75-145 m; both p<0.001), FVC (mild/moderate: +7.7%, 1.0-17.8%, p=0.002; severe/critical: +11.3%, 1.0-16.9%, p<0.001) and SF-36 mental component (mild/moderate: +5.6 points, 1.4-9.2 points, p=0.071; severe/critical: +14.4 points, -0.6-24.5, p<0.001). No adverse event was observed. Our study shows that pulmonary rehabilitation is a feasible, safe and effective therapeutic option in COVID-19 patients independent of disease severity.
Sections du résumé
BACKGROUND
BACKGROUND
Coronavirus disease 2019 (COVID-19) can result in a large variety of chronic health issues such as impaired lung function, reduced exercise performance and diminished quality of life. Our study aimed to investigate the efficacy, feasibility and safety of pulmonary rehabilitation in COVID-19 patients and to compare outcomes between patients with a mild/moderate and a severe/critical course of the disease.
METHODS
METHODS
Patients in the post-acute phase of a mild to critical course of COVID-19 admitted to a comprehensive 3-week inpatient pulmonary rehabilitation programme were included in this prospective, observational cohort study. Several measures of exercise performance (6-min walk distance (6MWD)), lung function (forced vital capacity (FVC)) and quality of life (36-question short-form health survey (SF-36)) were assessed before and after pulmonary rehabilitation.
RESULTS
RESULTS
50 patients were included in the study (24 with mild/moderate and 26 with severe/critical COVID-19). On admission, patients had a reduced 6MWD (mild: median 509 m, interquartile range (IQR) 426-539 m; severe: 344 m, 244-392 m), an impaired FVC (mild: 80%, 59-91%; severe: 75%, 60-91%) and a low SF-36 mental health score (mild: 49 points, 37-54 points; severe: 39 points, 30-53 points). Patients attended a median (IQR) 100% (94-100%) of all provided pulmonary rehabilitation sessions. At discharge, patients in both subgroups improved in 6MWD (mild/moderate: +48 m, 35-113 m; severe/critical: +124 m, 75-145 m; both p<0.001), FVC (mild/moderate: +7.7%, 1.0-17.8%, p=0.002; severe/critical: +11.3%, 1.0-16.9%, p<0.001) and SF-36 mental component (mild/moderate: +5.6 points, 1.4-9.2 points, p=0.071; severe/critical: +14.4 points, -0.6-24.5, p<0.001). No adverse event was observed.
CONCLUSION
CONCLUSIONS
Our study shows that pulmonary rehabilitation is a feasible, safe and effective therapeutic option in COVID-19 patients independent of disease severity.
Identifiants
pubmed: 34095290
doi: 10.1183/23120541.00108-2021
pii: 00108-2021
pmc: PMC7957293
pii:
doi:
Types de publication
Journal Article
Comment
Langues
eng
Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: R. Gloeckl has nothing to disclose. Conflict of interest: D. Leitl has nothing to disclose. Conflict of interest: I. Jarosch has nothing to disclose. Conflict of interest: T. Schneeberger has nothing to disclose. Conflict of interest: C. Nell has nothing to disclose. Conflict of interest: N. Stenzel has nothing to disclose. Conflict of interest: C.F. Vogelmeier has nothing to disclose. Conflict of interest: K. Kenn has nothing to disclose. Conflict of interest: A.R. Koczulla has nothing to disclose.
Références
Eur Respir J. 2014 Dec;44(6):1428-46
pubmed: 25359355
Thorax. 2013 Nov;68(11):1015-20
pubmed: 23783372
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
Am J Phys Med Rehabil. 2020 Oct;99(10):865-869
pubmed: 32732746
Dement Geriatr Cogn Dis Extra. 2017 Sep 28;7(3):318-327
pubmed: 29118784
Thorax. 1999 Jul;54(7):581-6
pubmed: 10377201
Chest. 2005 Oct;128(4):2247-61
pubmed: 16236881
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Eur Respir J. 2020 Jun 25;55(6):
pubmed: 32586841
Ann Phys Rehabil Med. 2020 Nov;63(6):554-556
pubmed: 32315802
J Clin Med. 2020 May 21;9(5):
pubmed: 32455843
Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64
pubmed: 24127811
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Clin Exp Med. 2020 Nov;20(4):493-506
pubmed: 32720223
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Am J Physiol Lung Cell Mol Physiol. 2021 Feb 1;320(2):L257-L265
pubmed: 33355522
Eur J Phys Rehabil Med. 2021 Feb;57(1):166-170
pubmed: 33263249
Lancet Respir Med. 2020 Aug;8(8):750-752
pubmed: 32422177
Complement Ther Clin Pract. 2020 May;39:101166
pubmed: 32379637
Eur Respir J. 2020 Aug 13;:
pubmed: 32817258
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Am J Respir Crit Care Med. 2014 May 1;189(9):e15-62
pubmed: 24787074
Med Care. 2008 Mar;46(3):266-74
pubmed: 18388841
J Med Virol. 2021 Apr;93(4):1896-1899
pubmed: 33295637
Respir Med. 2020 Nov - Dec;174:106197
pubmed: 33120193
Monaldi Arch Chest Dis. 2020 Jun 23;90(2):
pubmed: 32573175
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155789
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33419891
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Eur Respir J. 2020 Nov 26;56(5):
pubmed: 33008936
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Respirol Case Rep. 2020 Oct 07;8(8):e00669
pubmed: 33042547